Paul Saritha, Rao Shripada, Kohan Rolland, McMichael Judy, French Noel, Zhang Guicheng, Simmer Karen
Department of Neonatology, King Edward Memorial Hospital for Women, Western Australia, Australia; Department of Neonatology, Princess Margaret Hospital for Children, Perth, Western Australia, Australia; Centre for Neonatal Research and Education, School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia.
J Paediatr Child Health. 2013 Oct;49(10):839-44. doi: 10.1111/jpc.12300. Epub 2013 Jun 26.
Poractant alfa and beractant are the commonly used animal derived surfactants in preterm infants with respiratory distress syndrome. Between 2005 and 2007, poractant alfa and beractant were alternated every month in our neonatal intensive care unit for 27 months. The aim of this study was to compare the outcomes of preterm infants who received poractant alfa versus beractant.
Single-centre, retrospective cohort study of inborn preterm infants <32 weeks gestation (23-31(+6) ).
Six hundred sixty-four preterm infants (<32 weeks) were born during the study period, of which 415 received surfactant (poractant alfa: 214; beractant: 201). Infants in the poractant alfa group were 2.8 days younger than beractant (27.0 ± 2.3 vs. 27.4 ± 2.3 weeks; P = 0.03). All other baseline characters including Clinical Risk Index for Babies II scores were similar for both groups. No significant differences were found for the following outcomes: death or chronic lung disease (78/212 vs. 59/200; P = 0.28); death (24/214 vs. 15/201, P = 0.24); moderate to severe chronic lung disease (63/212 vs. 46/200; P = 0.45) and moderate to severe disability (20/163 vs. 19/151, P = 0.98) between poractant alfa and beractant, respectively.
The results of our study do not support the need for preferential use of poractant alfa or beractant.
肺泡表面活性物质α和贝可肺泰是呼吸窘迫综合征早产儿常用的动物源性表面活性剂。2005年至2007年期间，我院新生儿重症监护病房每月交替使用肺泡表面活性物质α和贝可肺泰，共持续27个月。本研究旨在比较接受肺泡表面活性物质α与贝可肺泰治疗的早产儿的结局。
对孕周<32周（23 - 31(+6)）的足月儿进行单中心回顾性队列研究。
研究期间共出生664例孕周<32周的早产儿，其中415例接受了表面活性剂治疗（肺泡表面活性物质α组：214例；贝可肺泰组：201例）。肺泡表面活性物质α组婴儿比贝可肺泰组婴儿小2.8天（27.0 ± 2.3周 vs. 27.4 ± 2.3周；P = 0.03）。两组其他所有基线特征包括婴儿临床风险指数II评分均相似。两组在以下结局方面未发现显著差异：死亡或慢性肺病（78/212 vs. 59/200；P = 0.28）；死亡（24/214 vs. 15/201，P = 0.24）；中重度慢性肺病（63/212 vs. 46/200；P = 0.45）以及中重度残疾（20/163 vs. 19/151，P = 0.98）。
我们的研究结果不支持优先使用肺泡表面活性物质α或贝可肺泰。
